Leading cognitive-disorders specialist, Dr. William Shankle, will discuss vascular cognitive impairment, vascular dementia and the proposed clinical trial of VesCell™…
Positive DRDC findings support the next phase for bucillamine as Revive plans to pursue government-backed development opportunities, expand intellectual property…
SHELTON, CT / ACCESS Newswire / August 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader…
SHELTON, CT / ACCESS Newswire / August 10, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader…
mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved productCompany expects supply to be available in select retailers in…
Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines…
New Orders Growing; Production Growing; Employment Growing; Supplier Deliveries Slowing; Raw Materials Inventories Growing; Customers' Inventories Too Low; Prices Increasing;…
Launch targets acute viral infection and Long COVID markets through www.CorexaRx.com/Store TAMPA, FL / ACCESS Newswire / July 31, 2026…
Calgary, Alberta--(Newsfile Corp. - July 30, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased…
Calgary, Alberta--(Newsfile Corp. - July 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"),…